Search PubMed⌕ Search

Biomedical subjects

K Imanaka

Publications and source records attributed to K Imanaka.

At least 91 records · Page 5Linked to original sources
PubMed1987

Myocardial ultrastructure in Kearns-Sayre syndrome.

Myocardial ultrastructural changes are described in a twenty-five-year-old female with typical Kearns-Sayre syndrome. The electrocardiogram revealed complete atrioventricular block with an occasional torsades de pointes type of ventricular tachycardia. His bundle recording demonstrated HV block with normal AH interval. An endomyocardial biopsy showed "ragged-red fibers" by the modified Gomori trichrome stain, and on electron microscopy there were increased numbers of morphologically abnormal mitochondria: ie, gian mitochondria, a whorled pattern of the cristae, and electron-dense substances, and paracrystalline inclusions in the mitochondria. The patient has been well since pacemaker implantation, but she may develop a clinically overt cardiomyopathy due to progression of myocardial involvement.

Adult↗
PubMed1987

[Radiation therapy of metastatic sites in hepatoma].

Ten patients with hepatoma who had received radiotherapy for their metastatic sites have been reviewed. In 13 lesions of bone metastasis in 7 patients complete pain relief from 5 lesions (38%) was achieved, while partial relief (54%) was obtained in other lesions. Of 3 patients with a brain metastasis, one attained complete symptomatic improvement with a 65% tumor reduction, and one of the remaining two gained a symptomatic palliation. In a patient with two pulmonary metastases, intraarterial chemotherapy showed a more remarkable effect when treatment was combined with radiotherapy than intraarterial chemotherapy alone. It may be concluded that radiation therapy is effected modality for palliating metastatic lesions of hepatoma.

Aged↗
PubMed1986

[Clinical evaluation of combination therapy with cefoxitin and amikacin in complicated urinary tract infections].

The clinical efficacy of combination therapy using Cefoxitin (CFX) and Amikacin (AMK) was studied in 19 patients with complicated urinary tract infections. Patients received 2 g of CFX i.v. and 100 mg of AMK i.m. twice a day. The overall clinical efficacy of treatment was evaluated by the criteria proposed by the UTI Committee, Japan, as excellent, moderate or poor. The overall clinical efficacy was excellent in 89%, moderate in 5% and poor in 5% of the patients. Of the 21 strains isolated from the patients, 20 strains (95%) were eradicated. No subjective side effects were observed. Drug-related aggravation in laboratory tests were observed slight elevations of glutomic-oxalacefic transaminase, glutamic-pyruvic transaminase and alkaliphosphatase in 2 cases, but all of them were minimal and reversible. Underlying condition-related aggravation was observed a slight elevation of BUN and creatinine clearance in 1 case. These results suggest that the combination therapy with CFX and AMK might be useful in the treatment of complicated urinary tract infections.

Adolescent↗